Drug Profile
Research programme: malaria vaccine - Profectus Biosciences
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Profectus Biosciences
- Developer PATH; Profectus Biosciences
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria(Prevention) in USA (Parenteral)
- 16 Nov 2011 Profectus BioSciences receives follow-on grant from PATH Malaria Vaccines Initiative for malaria vaccine development
- 26 Aug 2009 Preclinical trials in Malaria prevention in USA (unspecified route)